Literature DB >> 30046575

Association between the lymph node ratio and hepatic tumor burden: importance for resectable colorectal liver metastases?

Kristoffer Watten Brudvik1, Kjetil Søreide2,3,4.   

Abstract

Entities:  

Year:  2018        PMID: 30046575      PMCID: PMC6036068          DOI: 10.21037/hbsn.2018.03.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  14 in total

1.  Prognostic significance of the lymph node ratio in stage IV colorectal cancer patients who have undergone curative resection.

Authors:  Tsuyoshi Ozawa; Soichiro Ishihara; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa; Takamitsu Kanazawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  Ann Surg Oncol       Date:  2014-11-15       Impact factor: 5.344

2.  Indicators of prognosis after hepatic resection for colorectal secondaries.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann; F P Gall
Journal:  Surgery       Date:  1991-07       Impact factor: 3.982

3.  Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway.

Authors:  J-H Angelsen; A Horn; H Sorbye; G E Eide; I M Løes; A Viste
Journal:  Br J Surg       Date:  2017-02-09       Impact factor: 6.939

Review 4.  The lymph node microenvironment and its role in the progression of metastatic cancer.

Authors:  Ethel R Pereira; Dennis Jones; Keehoon Jung; Timothy P Padera
Journal:  Semin Cell Dev Biol       Date:  2015-01-22       Impact factor: 7.727

5.  Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

Authors:  Bernhard Mlecnik; Marc Van den Eynde; Gabriela Bindea; Sarah E Church; Angela Vasaturo; Tessa Fredriksen; Lucie Lafontaine; Nacilla Haicheur; Florence Marliot; Daphné Debetancourt; Géraldine Pairet; Anne Jouret-Mourin; Jean-Francois Gigot; Catherine Hubert; Etienne Danse; Cristina Dragean; Javier Carrasco; Yves Humblet; Viia Valge-Archer; Anne Berger; Franck Pagès; Jean-Pascal Machiels; Jérôme Galon
Journal:  J Natl Cancer Inst       Date:  2018-01-01       Impact factor: 13.506

6.  The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.

Authors:  Kazunari Sasaki; Daisuke Morioka; Simone Conci; Georgios A Margonis; Yu Sawada; Andrea Ruzzenente; Takafumi Kumamoto; Calogero Iacono; Nikolaos Andreatos; Alfredo Guglielmi; Itaru Endo; Timothy M Pawlik
Journal:  Ann Surg       Date:  2018-01       Impact factor: 12.969

7.  Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.

Authors:  Akira Ooki; Kiwamu Akagi; Toshimasa Yatsuoka; Masako Asayama; Hiroki Hara; Yoji Nishimura; Hiroshi Katoh; Keishi Yamashita; Masahiko Watanabe; Kensei Yamaguchi
Journal:  J Gastrointest Surg       Date:  2017-03-01       Impact factor: 3.452

Review 8.  Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.

Authors:  K W Brudvik; S E Kopetz; L Li; C Conrad; T A Aloia; J-N Vauthey
Journal:  Br J Surg       Date:  2015-07-21       Impact factor: 6.939

9.  Qualitative and quantitative issues of lymph nodes as prognostic factor in colon cancer.

Authors:  Torhild Veen; Bjørn S Nedrebø; Kjartan Stormark; Jon Arne Søreide; Hartwig Kørner; Kjetil Søreide
Journal:  Dig Surg       Date:  2013-04-10       Impact factor: 2.588

10.  A study of lymph node ratio in stage IV colorectal cancer.

Authors:  Kristoffer Derwinger; Bengt Gustavsson
Journal:  World J Surg Oncol       Date:  2008-12-01       Impact factor: 2.754

View more
  1 in total

1.  Hepatobiliary case report and literature review of hepatic reactive lymphoid hyperplasia with positive anti-smooth muscle antibody and anti-nuclear antibody tests.

Authors:  Yong-Chang Zheng; Fu-Cun Xie; Kai Kang; Yue Shi; Yi-Lei Mao; Xin-Ting Sang; Shun-Da Du
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.